LivaNova today announced that its OSPREY trial of nerve stimulation for treating sleep apnea met its primary endpoints.

Tivic Health Systems (Nasdaq:TIVC) announced today that it completed enrollment in a study for its vagus nerve stimulation (VNS) device.

Tivic Health® Systems, Inc. (Nasdaq: TIVC), a health tech company developing and commercializing bioelectronic medicine, announced today that full enr ...

so it surprised the researchers that touch-sensing nerve cells responded to such stimulation. Further, this nerve cell type ...

Researchers identified 16 distinct types of nerve cells involved in human touch and compared them with those in mice and macaques, showing both shared and unique traits.

Market Opportunity Polaris Market Research estimates the global vagus nerve stimulation (VNS) market will grow from $8.59 billion in 2021 to $21.3 billion in 2030, a 10.6% CAGR over the forecast ...

In a small early trial using a transcranial magnetic stimulation procedure, scientists were able to target a key brain ...

At-home brain stimulation therapy can safely and effectively treat severe to moderate depression, a new clinical trial shows. Rates of treatment response and depression remission were three times ...